Researchers from UQ's Queensland Brain Institute are set to conduct a world-first trial into the link between prenatal vitamin D levels and schizophrenia prevalence.

Throughout the world, scientists are attempting to recognize and treat schizophrenic disorders at an earlier stage.

Researchers from UQ's Queensland Brain Institute are set to conduct a world-first trial into the link between prenatal vitamin D levels and schizophrenia prevalence.

People with schizophrenia have an increased number of unusual chromosomal changes, particularly structural changes that have the potential to alter the function of the genes. These results were published today in the scientific journal Nature.

Schizophrenia is one of the most serious mental illnesses and is accompanied by symptoms that include delusions and blunted affect. Environmental as well as genetic factors form a complex interplay that leads to the illness. Two papers published in the Internet editions of the professional journals "Nature" and "Nature Genetics" have offered a ground-breaking step in the complex and extraordinarily difficult search for relevant genetic factors.

Researchers have discovered new genes linked to schizophrenia, it has been revealed.

A multinational group of investigators has discovered that people suffering from schizophrenia are far more likely to carry rare chromosomal structural changes of all types, particularly those that have the potential to alter gene function.

Both schizophrenia and bipolar disorder can be disabling conditions, and both present clinically with significant mood and psychotic symptoms. These two illnesses also share genetic variants that might be involved in the predisposition to both disorders.

Schizophrenia is a disease that strikes an average of 4000 Belgians every year. The causes of this psychiatric disorder are not yet clear.

Biological Psychiatry is particularly proud to announce the publication of an issue dedicated to the product of the National Institute of Mental Health (NIMH) Cognitive Neuroscience Approaches to the Treatment of Impaired Cognition in Schizophrenia, or CNTRICS, initiative.

A protein found in immune cells may be a reliable marker for schizophrenia risk, report researchers in a new proteomics study appearing in the July issue of Molecular and Cellular proteomics.

Alterations in a molecular brain pathway activated by marijuana may contribute to the cognitive symptoms of schizophrenia, according to a report in the July issue of Archives of General Psychiatry, one of the JAMA/Archives journals.